Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Cybin

Psyched: Psilocybin Therapy Effective After One Year, Cybin & Deepak Chopra, Enveric Psilocybin Cancer Study

Psilocybin received yet another confirmation of its beneficial effects in the treatment of major depressive disorder, this time, in the long term. A new Johns Hopkins review study found that the positive effects of just two sessions of psilocybin-assisted psychotherapy can last for over one year in most patients with…

Cybin, Deepak Chopra Announce Partnership For Psychedelics Awareness And Education

Cybin, Deepak Chopra Announce Partnership For Psychedelics Awareness And Education

Psychedelics-focused biotech company Cybin Inc. (NYSE: CYBN) announced that it has formed a partnership with The Chopra Foundation, a not-for-profit founded by alternative medicine and new age author Deepak Chopra.

Cybin, MindMed, And Field Trip Health Headline PSYC's First CEO Round Table Event

Cybin, MindMed, And Field Trip Health Headline PSYC's First CEO Round Table Event

Media company Global Trac Solutions, Inc. (OTCP:PSYC) and authorities behind psychedelic news and information platform Psychedelic Spotlight, announced that Psychedelic Spotlight will host its first “CEO Roundtable” on Feb. 15.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Mind Medicine, Cybin Among Top Psychedelic Movers Of Today

GAINERS: Revive Therapeutics (OTC: RVVTF) shares closed up 2.51% at $0.22 LOSERS: Mind Medicine (NASDAQ: MNMD) shares closed down 8.09% at $1.25 Cybin (AMEX:CYBN) shares closed down 6.25% at $1.05 ATAI Life SciencesGAINERS:

Allied, Cybin Among Top Psychedelic Movers Of Today

GAINERS: Allied (OTC:ALID) shares closed up 7.39% at $1.89

Cybin Receives U.S. Patent For Its Proprietary DMT Compound To Treat Anxiety Disorders

Psychedelics company Cybin Inc. (NEO: CYBN) (AMEX: CYBN) announced that the U.S. Patent and Trademark Office has granted U.S. patent 11,242,318 to the company’s investigational deuterated dimethyltryptamine (“DMT”) compound CYB004.

Mindset Pharma, Cybin Among Top Psychedelic Movers Of Today

GAINERS: Awakn Life Sciences (OTC:AWKNF) shares closed up 3.51% at $1.62

inkl

Read news from The Economist, FT, and more,
with one subscription

Psychedelic Stock Gainers And Losers From January 18, 2022

Psychedelic Stock Gainers And Losers From January 18, 2022

GAINERS: Cybin (AMEX:CYBN) shares closed up 1.90% at $1.07

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Field Trip Health

Psychedelic Spotlight

ATAI Life Sciences

Awakn Life Sciences

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

249,175 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play